In short
This article discusses the use of the A/Wisconsin/67/2022 (H1N1)Pdm09-Like Strain (A/Georgia/12/2022 CVR-167) in clinical trials for influenza vaccines. This strain is one of the components in the Flucelvax Tetra vaccine, which is being studied to assess its safety, effectiveness, and long-term outcomes in preventing influenza.
At a glance
- Vaccine Name
- Flucelvax Tetra
- Strain Studied
- A/Wisconsin/67/2022 (H1N1)Pdm09-Like Strain (A/Georgia/12/2022 CVR-167)
- Vaccine Type
- Influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
- Administration Method
- Intramuscular injection
- Dosage
- 0.5 ml
- Other Strains in Vaccine
- B/Phuket/3073/2013-Like Virus, B/Austria/1359417/2021-Like Strain, A/Darwin/6/2021(H3N2)-Like Strain
- Marketing Authorization
- EU/1/18/1326/003
- Manufacturer
- Seqirus Netherlands B.V.
What is A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN?
A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN (A/GEORGIA/12/2022 CVR-167) is a component of the influenza vaccine known as Flucelvax Tetra. This strain is specifically designed to protect against a type of influenza A virus, which is one of the main types of flu viruses that circulate among humans. The term "H1N1" refers to specific proteins on the surface of the virus, which help identify it.
Purpose of the Vaccine
The primary purpose of this vaccine component is to prevent influenza, commonly known as the flu. Influenza is a contagious respiratory illness that can cause mild to severe illness, and in some cases, can lead to hospitalization or even death, especially in high-risk groups.
Vaccine Composition
Flucelvax Tetra, which contains the A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN, is a quadrivalent vaccine. This means it protects against four different flu viruses. The vaccine includes:
- A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN (A/GEORGIA/12/2022 CVR-167): This is the strain we're focusing on, which protects against a specific type of H1N1 influenza A virus.
- A/DARWIN/6/2021(H3N2)-LIKE STRAIN: This protects against another type of influenza A virus.
- B/AUSTRIA/1359417/2021-LIKE STRAIN: This protects against one lineage of influenza B virus.
- B/PHUKET/3073/2013-LIKE VIRUS: This protects against another lineage of influenza B virus.
How is it Administered?
The Flucelvax Tetra vaccine, which contains the A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN, is administered via intramuscular injection. This means the vaccine is injected directly into a muscle, typically in the upper arm for adults.
Dosage Information
The maximum daily dose and maximum total dose of the Flucelvax Tetra vaccine is 0.5 ml. This single dose contains all four strains of the influenza virus, including the A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN. The vaccine is typically given once per flu season, which is why the maximum treatment period is listed as 1 day.
Benefits of the Vaccine
The inclusion of the A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN in the Flucelvax Tetra vaccine offers several benefits:
- Protection against current strains: This strain is selected based on surveillance data to match the H1N1 viruses expected to circulate during the flu season.
- Broad coverage: As part of a quadrivalent vaccine, it helps provide protection against multiple flu strains.
- Reduced risk of flu-related complications: By preventing influenza infection, it can help reduce the risk of flu-related complications, hospitalizations, and deaths.
- Cell-based production: Flucelvax Tetra is prepared in cell cultures, which can potentially offer advantages in terms of production speed and avoiding egg-based allergies.
It's important to note that while this vaccine component is designed to provide protection against specific flu strains, the effectiveness can vary from season to season and person to person. However, vaccination remains one of the most effective ways to prevent flu and its potential complications.